Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No.	Product name	CAS No.	Purity	Chemical Structure
T73689	Daclizumab	152923-56-3	98%	Daclizumab
T73689	Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA. Daclizumab (Zenapax) can inhibit the binding of...			Daclizumab
T73695	Canakinumab	914613-48-2	98%
T73695	Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody.Canakinumab has been shown to inhibit human and chorioallantoic monkey IL-1β, wit...
T73698	Basiliximab	179045-86-4	98%	Basiliximab
T73698	Basiliximab (CHI 621) is a chimeric mouse/human IgG1 monoclonal recombinant antibody against the interleukin-2 receptor. Basiliximab has good immunosuppressive a...			Basiliximab
T76671	Amatuximab	931402-35-6	98%	Amatuximab
T76671	Amatuximab (MORab-009) is a chimeric IgG1/k monoclonal antibody humanized against cell surface mesoleptin (MSLN) with antitumor activity for the treatment of sol...			Amatuximab
T76672	Aprutumab	1634620-63-5	98%	Aprutumab
T76672	Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize ...			Aprutumab
T76673	Bemarituzumab	1952272-74-0	98%	Bemarituzumab
T76673	Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applica...			Bemarituzumab
T76674	Cibisatamab	1855925-27-7	98%
T76674	Cibisatamab is a T-cell bispecific antibody that acts as a T-cell splicer.Cibisatamab targets carcinoembryonic antigen (CEA) on cancer cells and CD3 on T-cells, ...
T76681	Fresolimumab	948564-73-6	98%	Fresolimumab
T76681	Fresolimumab (GC1008) is a specific human anti-transforming growth factor β monoclonal antibody that binds to the active forms of human TGFβ1, TGFβ2, and TGFβ3 a...			Fresolimumab
T76682	Galcanezumab	1578199-75-3	98%	Galcanezumab
T76682	Galcanezumab is a humanized IgG4 monoclonal antibody targeting the CGRP ligand, which binds to the ligand calcitonin gene-related peptide. Galcanezumab can be us...			Galcanezumab
T76684	Girentuximab	916138-87-9	98%
T76684	Girentuximab (G250) is a potent anti-carbonic anhydrase IX (CAIX) monoclonal antibody with anticancer activity for the study of uroepithelial carcinoma PET (ZiPU...
T76685	Glofitamab	2229047-91-8	98%
T76685	Glofitamab (RO7082859) is a novel bivalent antibody directed against CD20-binding T cells.Glofitamab promotes T cell proliferation and activation and tumor cell ...
T76687	Ibalizumab	680188-33-4	98%
T76687	Ibalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 r...
T76690	Mavrilimumab	1085337-57-0	98%	Mavrilimumab
T76690	Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that has an affinity for the α subunit of the granulocytic-macrophage colony-stimulating...			Mavrilimumab
T76691	Monalizumab	1228763-95-8	98%	Monalizumab
T76691	Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NK...			Monalizumab
T76692	Mosunetuzumab	1905409-39-3	98%	Mosunetuzumab
T76692	Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to en...			Mosunetuzumab
T76696	Onvatilimab	1969313-51-6	98%	Onvatilimab
T76696	Onvatilimab (JNJ-61610588) is a human IgG1 κ-anti-Vista (T-cell-activated V-domain Ig inhibitor) monoclonal antibody. Onvatilimab has antitumor activity and can ...			Onvatilimab
T76698	Rovalpituzumab	1613313-01-1	98%	Rovalpituzumab
T76698	Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3). Rovalpituzumab can be used to synthesize antibody-active molecule conjug...			Rovalpituzumab
T76699	Sabatolimab	2252262-24-9	98%	Sabatolimab
T76699	Sabatolimab (MBG453), a humanized IgG4 (S228P) antibody targeting TIM-3, is a potent inhibitory receptor that regulates adaptive and innate immune responses. Sab...			Sabatolimab
T76700	Simtuzumab	1318075-13-6	98%	Simtuzumab
T76700	Simtuzumab is a monoclonal antibody against lysyl oxidase-like protein 2 (LOXL2). Simtuzumab can be used to treat primary sclerosing cholangitis (PSC) and is not...			Simtuzumab
T76702	Sutimlimab	2049079-64-1	98%	Sutimlimab
T76702	Sutimlimab is a novel monoclonal antibody targeting complement protein C1. Sutimlimab is commonly used as a C1 inhibitor to treat cold agglutina-associated hemol...			Sutimlimab